Navigation Links
Investigation Findings, Corroborated by Empirical Evidence of the,Schisandra Berry as Cardio-Tonic in Traditional Chinese Medicine,for Hundreds of Years, Support the Use of Schisandrin B in the,Prevention and Treatment of IHD

SEATTLE--(BUSINESS WIRE)--May 29, 2007 - Mitopharm Corporation, Inc. (Pink Sheets:MTPM), releases the results of a research paper where Professor Dr. Robert Ko published the beneficial effects of Schisandrin B, the precursor of (-) Schisandrin B - a novel discovery by Dr. Ko - on Ischemic Heart Disease.

In a research paper entitled "SCHISANDRIN B PROTECTS AGAINST MYOCARDIAL ISCHEMIA-REPERFUSION INJURY BY ENHANCING MYOCARDIAL GLUTATHIONE ANTIOXIDANT STATUS"; Yim and Ko; Molecular and Cellular Biochemistry 1999; 196: 151-156, Professor Dr. Robert Ko published the beneficial effects of Schisandrin B, the precursor of (-) Schisandrin B - a novel discovery by Dr. Ko - on Ischemic Heart Disease.

Ischemic heart disease (IHD) is the major cause of death in most industrialized countries. Following the removal of blood clot in the coronary artery, reperfusion of the previously blood-deprived myocardium can cause additional tissue damage. This phenomenon of ischemia-reperfusion (I-R) injury is an important cause of heart dysfunction and eventually death in patients suffering from IHD. Agents that offer heart protection against I-R injury is therefore of great therapeutic value in the prevention and treatment of IHD.

Schisandrin B, an active ingredient from Schisandra Berry, a well-known cardio-tonic in traditional Chinese medicine, has been shown to possess antioxidant properties. This investigation aims to examine whether Schisandrin B can protect against I-R injury in the heart. The results demonstrate for the first time cardio-protection afforded by Schisandrin B against I-R injury BY ENHANCING MYOCARDIAL GLUTATHIONE ANTIOXIDANT STATUS. In contrast, Dimethyl Diphenyl Bicarboxylate (DDB), an anti-hepatitis drug with a similar chemical structure to Schisandrin B, does not produce any cardio-protective effect or enhance tissue antioxidant status. This bespeaks much of the unique ability of Schisandrin B to e nhance the free radical scavenging capacity of the heart, thereby protecting against I-R injury.

The finding, which is corroborated by empirical evidence of the Schisandra berry as cardio-tonic in Traditional Chinese Medicine for hundreds of years, supports the use of Schisandrin B in the prevention and treatment of IHD.

Since the publication of this finding, Dr. Ko has identified an isomer of Schisandrin B, (-) Schisandrin B, a novel discovery, which possesses a more potent pharmacological profile than that of Schisandrin B. Patented use of this newly discovered compound, (-) Schisandrin B, for the prevention and treatment of Ischemic Heart Disease has been applied for with the US Patent and Trademark Office.

For a copy of this research report, please contact the publisher, Molecular and Cellular Biochemistry.

About the Company

MitoPharm Corporation is a biotechnology company in the research & development, marketing and sale of drugs, dietary supplements, and functional beverages. The initial products are based on a newly discovered compound (the "Compound") that is the result of over 15 years of research and development by one of its founding shareholders, the Hong Kong University of Science and Technology ("HKUST"). MitoPharm believes that its products have the potential to play a significant role in addressing the aging concerns of the baby boomers, the heart-health and heart-diseases markets, and the segment of the population that is physically active.

At HKUST, scientific studies have identified biochemical actions of MitoPharm's key Compound, demonstrating that it enhances the mitochondrial glutathione antioxidant status, a crucial factor in maintaining mitochondrial function and cell survival, and also induces the expression of heat shock proteins, another group of important molecules for cell protection. Management's research indicates that these biochemical actions differentiate the Compound f rom other existing, known compounds, either synthetic or naturally occurring, in its ability to protect organs including the heart, the liver, and the brain.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations, are generally identifiable by the use of words such as "believe," "expect," "intend," "anticipate," "estimate," "project," or similar expressions. These forward-looking statements relate to, among other things, expectations of the business environment in which the Company operates, projections of future performance, potential future performance, perceived opportunities in the market, and statements regarding the Company's mission and vision. The Company's actual results, performance, and achievements may differ materially from the results, performance, and achievements expressed or implied in such forward-looking statements.


Mogul IR
Robert Adams, 713-401-9333 (Investor Relations)


Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
(Date:12/1/2015)... During the recent 2015 Transcatheter Cardiovascular ... CA , Medinol Ltd. continued to introduce ... a satellite symposium, "The BioNIR eDES: The Role ... a renowned physician panel discussed the key attributes ... Stent System and the Medinol eDES Coronary Stent ...
(Date:12/1/2015)... YORK , Dec. 1, 2015 Relmada Therapeutics, ... the treatment of chronic pain, announced today that the company ... will be held December 1-3 at the Luxe Sunset Boulevard ... Sergio Traversa , CEO of Relmada Therapeutics, will present on ... Eastern Time). . Please register at least ...
(Date:12/1/2015)... Dec. 1, 2015  InCarda Therapeutics, Inc. (InCarda), a ... of therapies for cardiovascular conditions via the inhalation route, ... in Australia . InCarda is planning ... Australia in the first half of ... medical centers in Adelaide and ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... The workstation boundaries for ... IMAGE Information Systems launches MED-TAB™ -- the world’s first portable DICOM-calibrated medical image ... 29 to December 4, 2015. , MED-TAB is expected to change teleradiology ...
(Date:12/1/2015)... ... , ... The importance of volumetric breast density assessment for ... abstracts accepted for presentation here, at the 101st Annual Radiology Society of North ... of Volpara Solutions’ quantitative breast imaging software tools for providing breast imaging and ...
(Date:12/1/2015)... ... December 01, 2015 , ... For ... That is why Hollister Incorporated has launched the VaPro Plus Pocket™ touch free ... in the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice President North ...
(Date:12/1/2015)... ... December 01, 2015 , ... SAN FRANCISCO, Calif. (December 1, ... organization has awarded Education and Developmental Therapies (EDT), an Applied Behavior Analysis (ABA) ... exceptional special needs providers that excel in synthesizing the areas of clinical quality, ...
(Date:12/1/2015)... ... December 01, 2015 , ... McLean, ... been awarded a fixed price per sprint agile development contract to support the ... million over five years, provides software engineering, infrastructure, as well as operations and ...
Breaking Medicine News(10 mins):